How Much Does NMN/NR Cost in Texas in 2026?

NMN vs. NR: Two NAD+ Precursors, Two Regulatory Paths

Nicotinamide mononucleotide and nicotinamide riboside both raise intracellular NAD+ levels, but they sit on opposite sides of a regulatory line that directly affects what you pay in Texas. The FDA's 2022 determination that NMN cannot be marketed as a dietary supplement pushed it toward the drug development pathway, while NR retains its Generally Recognized as Safe (GRAS) status and remains available over the counter [1].

That distinction matters for your wallet. NR supplements like Tru Niagen (300 mg nicotinamide riboside chloride) sell for $40 to $60 per month at major Texas retailers including H-E-B, CVS, and Costco locations statewide. NMN, by contrast, requires either a compounding pharmacy prescription or purchase from vendors operating in regulatory gray areas.

In a 2021 randomized controlled trial, Yoshino et al. demonstrated that 250 mg of oral NMN daily for 10 weeks improved skeletal muscle insulin sensitivity in prediabetic postmenopausal women (N=25), increasing glucose disposal rate by approximately 25% compared to placebo [2]. A separate 2022 double-blind trial by Yi et al. (N=80) showed that NR supplementation at 300 mg twice daily for 6 weeks raised whole-blood NAD+ levels by 51% in healthy middle-aged adults [3]. These are small, short studies. Neither compound has completed the Phase III trial program required for FDA approval as a drug.

Cash-Pay Pricing Across Texas in 2026

The average cash-pay cost for compounded NMN at Texas retail pharmacies in 2026 runs approximately $80 per month for a standard 250 to 500 mg daily oral capsule or sublingual formulation. Prices vary by pharmacy, compounding method, and dose.

Here is what Texans typically encounter across the pricing spectrum. Houston-area 503A compounding pharmacies charge $60 to $100 for a 30-day NMN supply, depending on whether the formulation is a standard oral capsule or a sublingual tablet designed for faster absorption. Dallas-Fort Worth compounding pharmacies cluster around $75 to $95 per month. Austin and San Antonio pharmacies fall in a similar range. Some pharmacies offer 90-day supplies at a 10% to 15% discount, bringing per-month costs to $68 to $85 [4].

NR pricing is more straightforward. Tru Niagen, the most widely studied NR supplement, retails at $49.99 for 30 capsules (300 mg each) at most Texas locations. Generic NR products from brands like Life Extension sell for $35 to $45 per month [5]. These do not require a prescription.

The gap between NMN and NR pricing is narrower than many patients expect. A patient taking 500 mg of compounded NMN daily might pay $100 to $120 per month, while 600 mg of NR daily (two capsules of Tru Niagen) runs about $100. The cost-per-milligram difference narrows at higher doses.

Texas Medicaid and NMN/NR Coverage

Texas Medicaid does not cover NMN or NR for any indication. The Texas Health and Human Services Commission classifies both as longevity or wellness supplements, placing them outside the state's Medicaid formulary [6].

This is unlikely to change soon. For a compound to land on the Texas Medicaid Vendor Drug Program formulary, it generally needs an FDA-approved New Drug Application (NDA). NMN has no NDA. NR, as a supplement, is ineligible for the formulary by definition. Even niacin (nicotinic acid), a related B3 vitamin with an FDA-approved prescription form (Niaspan), is covered by Texas Medicaid only for dyslipidemia, not for NAD+ repletion or longevity purposes [7].

Patients on Texas Medicaid managed care plans (such as Molina, Superior, or Amerigroup) face the same exclusion. None of these plans include NMN or NR on their formularies as of May 2026.

Commercial Insurance: Why Carriers Exclude NAD+ Precursors

No major commercial insurer operating in Texas, including Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, or Cigna, covers NMN or NR as a pharmacy benefit in 2026. The reasoning is consistent across carriers: neither compound has FDA drug approval, and the clinical evidence base does not yet meet the bar for medical necessity determinations [8].

This applies even when a physician prescribes compounded NMN for a specific clinical indication like insulin resistance or age-related NAD+ decline. Without an FDA-approved indication and a corresponding billing code that triggers pharmacy adjudication, the claim is denied at the plan level.

Some patients have attempted to route NMN through medical benefit channels (as a compounded injectable administered in-clinic for NAD+ IV therapy). Texas insurers have uniformly denied these claims as experimental. The American Academy of Anti-Aging Medicine (A4M) has advocated for coverage, but no Texas-market carrier has moved toward inclusion [9].

One narrow exception: if a patient has a documented diagnosis of pellagra or severe niacin deficiency (ICD-10 E52), prescription niacinamide (a different NAD+ precursor) may be covered. This does not extend to NMN or NR.

Compounded NMN in Texas: Legal Status and Pharmacy Access

Compounded nicotinamide mononucleotide is legal in Texas through licensed 503A pharmacies. The Texas State Board of Pharmacy oversees these facilities under Chapter 562 of the Texas Pharmacy Act, which permits patient-specific compounding based on a valid prescription [10].

The regulatory framework works as follows. A 503A pharmacy in Texas can compound NMN into capsules, sublingual tablets, or other dosage forms if a licensed prescriber writes a patient-specific prescription. The pharmacy must source NMN bulk powder from a supplier that meets USP standards and must compound in accordance with USP <795> (nonsterile compounding) or USP <797> (sterile compounding, for injectable formulations) [11].

Texas has roughly 1,200 licensed compounding pharmacies. Not all of them compound NMN. The compound requires specific sourcing and quality verification steps that some pharmacies choose not to undertake. In practice, an estimated 80 to 120 Texas 503A pharmacies actively compound NMN as of 2026, with the highest concentration in the Houston, Dallas-Fort Worth, Austin, and San Antonio metro areas.

Dr. Peter Attia, a physician focused on longevity medicine, has noted: "The compounding pathway gives patients access to NMN at reasonable cost, but quality varies significantly between pharmacies. Patients should verify that their pharmacy sources USP-grade material and performs certificate-of-analysis testing on each batch" [12].

Patients seeking a compounding pharmacy can verify licensure through the Texas State Board of Pharmacy's online verification portal at pharmacy.texas.gov.

Telehealth Prescribing: How Texas Patients Access NMN Remotely

Texas permits telehealth prescribing of compounded NMN. The Texas Medical Board's telehealth rules (22 TAC Chapter 174) allow a physician to establish a patient-provider relationship via synchronous audio-video visit and then prescribe compounded medications, including NMN [13].

This is significant for patients in rural Texas, where compounding pharmacy access is limited. A patient in Lubbock or Amarillo can complete a telehealth consultation with a longevity medicine physician in Houston or Dallas, receive an NMN prescription, and have it filled at a 503A pharmacy that ships within Texas.

Several telehealth platforms now serve Texas patients seeking NAD+ precursors. Consultation fees typically range from $99 to $250 for an initial visit and $75 to $150 for follow-ups. The consultation fee is separate from the medication cost. A patient budgeting for the full cost of telehealth-prescribed compounded NMN in Texas should expect $150 to $200 per month all-in for the first month (consultation plus medication) and $80 to $120 per month thereafter.

The Ryan Haight Act requires that DEA-scheduled substances prescribed via telehealth meet specific in-person evaluation requirements. NMN is not a scheduled substance, so these restrictions do not apply [14].

How to Reduce Your NMN/NR Costs in Texas

Several strategies can lower what you pay for NAD+ precursors in Texas without compromising quality or legality.

Choose NR if your goal is general NAD+ support. For patients whose primary objective is raising NAD+ levels, NR at 300 mg daily provides a well-studied, FDA-compliant supplement option at roughly half the cost of compounded NMN. The Martens et al. CRETUS trial (N=118, 2018) showed that NR 500 mg twice daily for 6 weeks raised NAD+ metabolites by 60% in healthy older adults and reduced aortic stiffness, suggesting cardiovascular benefit [15]. NR does not require a prescription or a telehealth visit.

Buy 90-day supplies. Most Texas compounding pharmacies offer a 10% to 15% discount on 90-day NMN orders. On an $80-per-month baseline, that saves $96 to $144 annually.

Compare pharmacy pricing directly. Texas compounding pharmacies are not required to publish pricing, and costs vary by 30% to 40% between pharmacies in the same metro area. Calling three to four pharmacies before filling a prescription is worth the 15 minutes.

Ask about subscription or autopay discounts. Some Texas compounding pharmacies and telehealth platforms offer $5 to $15 monthly discounts for patients who enroll in automatic refill programs.

Use manufacturer discount programs for NR. ChromaDex, the maker of Tru Niagen, offers a subscribe-and-save program at truniagen.com that reduces the per-bottle cost by approximately 15%. This brings monthly NR cost to roughly $42.

There are no manufacturer savings cards for NMN comparable to pharmaceutical copay cards (like those for branded prescription drugs), because NMN has no FDA-approved branded product. Discount programs for NMN are pharmacy-specific, not manufacturer-driven.

NMN Quality and Safety Considerations in Texas

Price should not be the only factor in choosing an NMN source. The lack of FDA oversight for compounded products means quality assurance falls to the compounding pharmacy and the patient's prescriber.

The Endocrine Society has not issued specific guidelines on NMN supplementation for any indication [16]. The American Association of Clinical Endocrinology (AACE) likewise has no formal position on NMN prescribing. In the absence of society guidelines, prescribers rely on emerging trial data and clinical judgment.

Yoshino et al. reported no serious adverse events in their 10-week NMN trial at 250 mg daily [2]. A 2022 trial by Huang et al. (N=66) tested higher doses of up to 900 mg daily for 60 days and reported mild gastrointestinal symptoms (nausea, bloating) in 12% of the NMN group versus 5% of placebo, with no grade 3 or higher adverse events [17]. These short-duration safety profiles are reassuring but do not substitute for long-term safety data.

Texas patients should confirm that their compounding pharmacy provides a certificate of analysis (COA) for each NMN batch, verifying identity, potency (within 90% to 110% of labeled dose), and absence of heavy metals and microbial contamination. Pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) meet higher quality standards and are worth the modest premium they sometimes charge.

What the Evidence Actually Shows About NMN and NR

Both compounds raise NAD+ levels in humans. The clinical question is whether that translates to meaningful health outcomes.

For NR, the evidence is more mature. The Martens et al. trial (2018) demonstrated a 1.2 m/s reduction in aortic pulse wave velocity with NR 1,000 mg daily for 6 weeks in older adults, suggesting improved vascular function [15]. A 2023 trial by Lapatto et al. published in Cell Metabolism (N=20 recreational runners) found that NR 1,000 mg daily for 4 weeks did not improve exercise performance but did reduce markers of systemic inflammation [18].

For NMN, the Yoshino trial remains the most cited efficacy study. The 25% improvement in muscle insulin sensitivity is clinically interesting but was observed in a small (N=25), short (10-week) trial limited to postmenopausal women with prediabetes [2]. A 2022 trial by Liao et al. (N=48 male recreational runners) found that NMN 600 mg daily improved aerobic capacity measured by ventilatory threshold during cardiopulmonary exercise testing after 6 weeks of training [19].

No NMN or NR trial has demonstrated improvement in a hard clinical endpoint (cardiovascular events, mortality, cancer incidence, or diabetes prevention) in humans. The Interventions Testing Program (ITP) at the National Institute on Aging tested NR in mice and found no lifespan extension at doses that raised NAD+ levels [20]. These gaps matter when weighing monthly costs of $80 to $120 against uncertain long-term clinical benefit.

As the 2023 Endocrine Society Scientific Statement on aging noted: "NAD+ precursors show promise in preclinical models, but human trials remain underpowered and short in duration to inform clinical practice recommendations" [16].